GET THE APP

Rationale of Using Common Antifibrotic Therapy in Post Covid Fibrosis
..

Pulmonary & Respiratory Medicine

ISSN: 2161-105X

Open Access

Review - (2021) Volume 11, Issue 1

Rationale of Using Common Antifibrotic Therapy in Post Covid Fibrosis

SM Abdullah Al Mamun*
*Correspondence: Senior Consultant & coordinator of Respi. SM Abdullah Al Mamun, Evercare Hospitals, Bangladesh, Email:
Evercare Hospitals, Bangladesh

Received: 10-Dec-2020 Published: 29-Jan-2021 , DOI: 10.37421/jprm.2020.11.524
Citation: SM Abdullah, Al Mamun, Rowshne, Jahan, Quazi tariqul ,islam and Tahera, Nazrin, et al. "Rationale of Using Common Antifibrotic Therapy in Post Covid Fibrosis". J Pulm Respir Med 11 (2021): 524.
Copyright: 2021 Mamun A, et al. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Retraction Note

The article entitled “Rationale of Using Common Antifibrotic Therapy in Post Covid Fibrosis” has been accepted for publication in the Journal of Pulmonary & Respiratory Medicine considering the statements provided in the article as personal opinion of the author which was found not having any conflict or biasness towards anything. Publisher took decision to make the article online solely based on the reviewer’s suggestion which considered the article not but a personal opinion of the author. However, it is found that the author has some personal concerns and issues, therefore, being retracted from the journal.

Google Scholar citation report
Citations: 1690

Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report

Pulmonary & Respiratory Medicine peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward